免疫组织化学染色检测肝癌组织中上皮细胞黏附分子和甲胎蛋白的共表达。
Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma.
机构信息
Departamento de Cirurgia, Hospital das Clínicas da Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Departamento de Medicina Social e Preventiva da Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
出版信息
Can J Gastroenterol Hepatol. 2018 Jul 19;2018:5970852. doi: 10.1155/2018/5970852. eCollection 2018.
BACKGROUND AND AIM
The epithelial cell adhesion molecule (EpCAM) has been proposed as a marker for cancer stem cells in human hepatocellular carcinoma (HCC) as well as in the development of novel target therapies. This study aimed to investigate the immunohistochemical expression of EpCAM and alpha-fetoprotein (AFP) in HCC patients and their association with clinicopathological characteristics.
METHODS
This study included Child-Pugh A HCC patients undergoing curative surgical resection.
RESULTS
A significant difference was observed in the ratio between the different phenotypes (p = 0.002), identifying 12 (29.3%) EPCAM positive tumors and 29 (70.7%) negative tumors. EpCAM+ expression was associated with AFP + (OR = 12.5, 95% CI, 1.9-84.1, p<0.001). In univariate analysis, a significant association was observed between AFP+ and EPCAM+ and the serum AFP level. A diameter of ≤ 5 cm was associated with EPCAM+, while angiolymphatic invasion was associated with APF+. In a multivariate analysis, only tumors of ≤ 5 cm were significantly associated with EpCAM+ (OR = 8.7; 95%CI, 1.27-100.0; p = 0.022). The overall survival rate was 74.9%, 69.4%, 69.4%, and 53.5% at 12, 24, 36, and 48 months, respectively.
CONCLUSION
A considerable number of patients with EpCAM+ HCC would benefit from a specific target therapy.
背景与目的
上皮细胞黏附分子（EpCAM）已被提议作为人类肝细胞癌（HCC）以及新型靶向治疗发展中癌症干细胞的标志物。本研究旨在研究 EpCAM 和甲胎蛋白（AFP）在 HCC 患者中的免疫组织化学表达及其与临床病理特征的关系。
方法
本研究纳入接受根治性手术切除的 Child-Pugh A HCC 患者。
结果
不同表型之间的比例存在显著差异（p = 0.002），鉴定出 12 例（29.3%）EpCAM 阳性肿瘤和 29 例（70.7%）阴性肿瘤。EpCAM+表达与 AFP+（OR = 12.5，95%CI，1.9-84.1，p<0.001）相关。在单因素分析中，AFP+和 EpCAM+与血清 AFP 水平之间存在显著相关性。直径≤5cm 与 EpCAM+相关，而血管淋巴管侵犯与 AFP+相关。在多因素分析中，只有直径≤5cm 的肿瘤与 EpCAM+显著相关（OR = 8.7；95%CI，1.27-100.0；p = 0.022）。总生存率分别为 12、24、36 和 48 个月的 74.9%、69.4%、69.4%和 53.5%。
结论
相当数量的 EpCAM+HCC 患者将受益于特定的靶向治疗。
Zotero 插件